News | December 12, 2024
Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Modernization and supply chain diversity drive new growth
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Subscribe To Our Newsletter & Stay Updated
